Table 2.
Impact of KIR on clinical outcomes in KIR ligand model.
| References | N | Disease | Donor | Graft manipulation | Clinical outcomes |
|---|---|---|---|---|---|
| Ruggeri et al. (36) | 92 | AML, ALL | HRD | TCD* | KIR ligand mismatch: higher EFS and OS, lower relapse (AML) KIR ligand mismatch: lower aGVHD2−4 |
| Davies et al. (41) | 175 | Mixed | URD | TCD*, TCR | KIR ligand mismatch: lower OS (myeloid cohort) |
| Giebel et al. (42) | 130 | Mixed | URD | TCD# | KIR ligand mismatch: higher OS and DFS, lower TRM |
| Schaffer et al. (43) | 190 | Mixed | URD | TCD*, TCD# | KIR ligand mismatch: higher IRM and TRM, and lower OS |
| Elmaagacli et al. (44) | 236 | CML | MSD, URD | TCR | KIR ligand mismatch: lower molecular relapse |
| Yabe et al. (45) | 1489 | Mixed | URD | TCD#, TCR | KIR ligand mismatch: higher aGVHD2/3−4 and lower OS (HLA-C mismatched transplants) |
| Verneris et al. (46) | 716 | Pediatric AL | URD | TCD#, TCR | KIR ligand mismatch: no significant impact on OS, DFS, relapse, TRM, or aGVHD. |
| Ruggeri et al. (47) | 112 | AML | HRD | TCD* | KIR ligand mismatch: lower relapse (CR group), higher EFS, and lower risk of relapse or death |
| Huang et al. (48) | 116 | Mixed | HRD | TCD# | KIR ligand mismatch: higher aGVHD2−4 and relapse, lower OS |
| Zhao et al. (49) | 64 | Mixed | HRD | TCD# | KIR ligand mismatch: higher aGVHD; |
| Michaelis et al. (50) | 57 | Mixed | HRD | TCD* | KIR ligand mismatch: lower EFS (AML) |
| Mancusi et al. (51) | 161 | AML, ALL | HRD | TCD* TCD*+Treg/Tcon |
NK-alloreactive donors: lower relapse and higher EFS (AML) |
| Yahng et al. (52) | 100 | AML | HRD | TCD# | KIR ligand mismatch (HVG): higher relapse and CMV reactivation, lower DFS |
| Zhao et al. (53) | 180 | Mixed | HRD | TCD# | KIR ligand match: lower CMV reactivation rate and higher IFN-γ expression |
| Wanquet et al. (54) | 144 | Mixed | HRD | TCD# | KIR ligand mismatch: lower relapse and higher PFS (no CR group) |
| Shimoni et al. (55) | 444 | AML, ALL | HRD | TCD# | KIR ligand mismatch: a trend of higher relapse (AML), lower OS |
MSD, matched sibling donor; URD, unrelated donor; HRD, haploidentical related donor; AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; CML, chronic myeloid leukemia; TCD, T cell depleted; TCR: T cell replete; Treg, regulatory T cells; Tcon, conventional T cells; aGVHD: acute graft vs. host disease; cGVHD: chronic graft vs. host disease; OS, overall survival; RFS, relapse free survival; DFS, disease free survival; EFS, event free survival; IRM: infection related mortality; TRM: transplant related mortality; CMV, cytomegalovirus.
TCD*: ex-vivo TCD.
TCD#: in-vivo TCD.